MedXCell Science was co-founded in 2018 by the University Hospital of Montpellier (CHU of Montpellier) in France and MedXCell SA, a Swiss company. It is the first time a French university hospital becomes shareholder of a private company.
MedXCell Science SAS implements several technologies developed by the CHU of Montpellier and its partners; the Institute of Regenerative Medicine and Biotherapy (IRMB), the Institut national de la santé et de la recherche médicale (Inserm) and the University of Montpellier. As part of the collaboration, MedXCell Science can count on more than 200 researchers and more than 20 years experience in the field of cell therapy.